Gut Microbiota-Targeted Interventions in the Management of Chronic Kidney Disease

Semin Nephrol. 2023 Mar;43(2):151408. doi: 10.1016/j.semnephrol.2023.151408. Epub 2023 Aug 22.

Abstract

Recent advances in microbiome research have informed the potential role of the gut microbiota in the regulation of metabolic, cardiovascular, and renal systems, and, when altered, in the pathogenesis of various cardiometabolic disorders, including chronic kidney disease (CKD). The improved understanding of gut dysbiosis in cardiometabolic pathologies in turn has led to a vigorous quest for developing therapeutic strategies. These therapeutic strategies aim to investigate whether interventions targeting gut dysbiosis can shift the microbiota toward eubiosis and if these shifts, in turn, translate into improvements in (or prevention of) CKD and its related complications, such as premature cardiovascular disease. Existing evidence suggests that multiple interventions (eg, plant-based diets; prebiotic, probiotic, and synbiotic supplementation; constipation treatment; fecal microbiota transplantation; and intestinal dialysis) might result in favorable modulation of the gut microbiota in patients with CKD, and thereby potentially contribute to improving clinical outcomes in these patients. In this review, we summarize the current understanding of the characteristics and roles of the gut microbiota in CKD and discuss the potential of emerging gut microbiota-targeted interventions in the management of CKD.

Keywords: Cardiovascular disease; chronic kidney disease; constipation; gut microbiota; nutrition supplements; plant-based diets.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases*
  • Dysbiosis / therapy
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Probiotics* / therapeutic use
  • Renal Insufficiency, Chronic* / therapy